NNC6019-0001 + Placebo (NNC6019-0001)
Phase 3Recruiting 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Conditions
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Trial Timeline
Oct 2, 2025 → Jun 29, 2029
NCT ID
NCT07207811About NNC6019-0001 + Placebo (NNC6019-0001)
NNC6019-0001 + Placebo (NNC6019-0001) is a phase 3 stage product being developed by Novo Nordisk for Transthyretin Amyloid Cardiomyopathy (ATTR CM). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07207811. Target conditions include Transthyretin Amyloid Cardiomyopathy (ATTR CM).
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07207811 | Phase 3 | Recruiting |
| NCT05442047 | Phase 2 | Completed |
Competing Products
20 competing products in Transthyretin Amyloid Cardiomyopathy (ATTR CM)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eplontersen Solution for Injection | AstraZeneca | Phase 1 | 33 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 77 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | AstraZeneca | Pre-clinical | 23 |
| Eplontersen | AstraZeneca | Phase 3 | 77 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 77 |
| NNC6019-0001 | Novo Nordisk | Phase 2 | 51 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 2 | 51 |
| Coramitug | Novo Nordisk | Phase 1 | 32 |
| Tafamidis | Pfizer | Pre-clinical | 22 |
| Tafamidis | Pfizer | Pre-clinical | 22 |
| tafamidis meglumine | Pfizer | Approved | 84 |
| Fx-1006A | Pfizer | Phase 2 | 51 |
| Tafamidis | Pfizer | Phase 3 | 76 |
| Tafamidis 61 milligrams | Pfizer | Pre-clinical | 22 |
| Treatment for TTR amyloidosis + Treatment for TTR amyloidosis | Pfizer | Pre-clinical | 22 |
| Vyndaqel | Pfizer | Pre-clinical | 22 |
| tafamidis | Pfizer | Phase 3 | 76 |
| Tafamidis | Pfizer | Approved | 84 |
| Tafamidis | Pfizer | Pre-clinical | 22 |
| Vyndamax (tafamidis 61mg) | Pfizer | Pre-clinical | 22 |